The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Official Title: A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 as a Single Agent in Patients With Selected Advanced Solid Tumors.
Study ID: NCT05867420
Brief Summary: The study is a Phase 1dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent in patients with selected advanced solid tumors.
Detailed Description: A two-part, dose-escalation and expansion study of ASKG915 was initiated to determine the safety, tolerability, PK and PD.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Columbia University Irving Medical Center, New York, New York, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Name: Barbara Hickingbottom, MD
Affiliation: Ask-Gene Pharma, Inc.
Role: STUDY_DIRECTOR